Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Ledger, G. A.    Gharib, H.    Related Articles in PubMed    PubMed Citation    PubMed

DIAGNOSIS AND TREATMENT

Genetic Testing in the Diagnosis and Management of Multiple Endocrine Neoplasia Type II

Gregory A. Ledger; Sundeep Khosla; Noralane M. Lindor; Stephen N. Thibodeau; and Hossein Gharib

15 January 1995 | Volume 122 Issue 2 | Pages 118-124

Purpose: To review significant advances in the early diagnosis and treatment of medullary thyroid carcinoma in patients with the multiple endocrine neoplasia II (MEN II) syndromes, advances made possible by the application of recently discovered genetic information.

Data Sources: Recently published English-language literature on linkage analysis and DNA analysis in the MEN II syndromes.

Study Selection: Articles on familial and sporadic forms of medullary thyroid carcinoma; pentagastrin-calcitonin determination; and genetic testing.

Data Extraction: Information from recent studies on 1) the usefulness and limitations of genetic testing, especially DNA and linkage analysis, in the early diagnosis of the familial form of thyroid carcinoma and 2) the correlation between the results of genetic testing and the results of biochemical screening.

Data Synthesis: Medullary thyroid carcinoma accounts for most of the morbidity and mortality among patients with the familial medullary thyroid carcinoma syndromes. Multiple endocrine neoplasia IIa and IIb and familial medullary thyroid carcinoma are inherited conditions with autosomal dominance and incomplete penetrance. Traditionally, diagnosis of and screening for these conditions have been done using pentagastrin stimulation tests and plasma calcitonin determinations. Recent genetic mapping, however, has assigned the genes responsible for these tumors to the pericentromeric region of chromosome 10. Available data suggest that mutations in exon 10, 11, or 16 of the RET proto-oncogene are responsible for MEN IIa and IIb and familial non-MEN medullary thyroid carcinoma. Thus, genetic testing can identify affected members of a kindred and will probably lead to early thyroidectomy and possible cure for gene carriers.

Conclusions: Early studies confirm the usefulness of DNA analysis in the diagnosis and treatment of patients with familial forms of medullary thyroid carcinoma. We review changes in the diagnosis and treatment of these patients and offer a strategy for operative intervention based on results of genetic testing.

Author and Article Information

From the Mayo Clinic and the Mayo Foundation, Rochester, Minnesota.
Requests for Reprints: Hossein Gharib, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

This article has been cited by other articles:

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				A. Khan and J. Bilezikian Primary hyperparathyroidism: pathophysiology and impact on bone Can. Med. Assoc. J., July 1, 2000; 163(2): 184 - 187. [Abstract] [Full Text] [PDF]

				R H Sijmons, R M W Hofstra, F A Wijburg, T P Links, R P Zwierstra, A Vermey, D C Aronson, G Tan-Sindhunata, G J Brouwers-Smalbraak, S M Maas, et al. Oncological implications of RET gene mutations in Hirschsprung's disease Gut, October 1, 1998; 43(4): 542 - 547. [Abstract] [Full Text] [PDF]

				I. Schuffenecker, M. Virally-Monod, R. Brohet, D. Goldgar, B. Conte-Devolx, L. Leclerc, O. Chabre, A. Boneu, J. Caron, C. Houdent, et al. Risk and Penetrance of Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A Families with Mutations at Codon 634 of the RET Proto-Oncogene J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 487 - 491. [Abstract] [Full Text]

				D. Russo, F. Arturi, E. Chiefari, D. Meringolo, D. Bianchi, B. Bellanova, and S. Filetti A Case of Metastatic Medullary Thyroid Carcinoma: Early Identification Before Surgery of an RET Proto-Oncogene Somatic Mutation in Fine-Needle Aspirate Specimens J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3378 - 3382. [Abstract] [Full Text] [PDF]

				M. Siegelman, A. Mohabeer, T. J. Fahey III, G. Tomlinson, C. Mayambala, S. Jafari, W. W. Noll, S. N. Thibodeau, and D. B. Dawson Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma Clin. Chem., March 1, 1997; 43(3): 453 - 457. [Abstract] [Full Text] [PDF]

				S. Guyetant, M.-C. Rousselet, M. Durigon, D. Chappard, B. Franc, O. Guerin, and J.-P. Saint-Andre Sex-Related C Cell Hyperplasia in the Normal Human Thyroid: A Quantitative Autopsy Study J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 42 - 47. [Abstract] [Full Text] [PDF]